A Phase 4 interventional study of Magic Touch drug eluting balloon based strategy and Drug-eluting stent-based strategy in Chronic Coronary Syndrome, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Cardiocentro Ticino · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions.
Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.
Patients at coronary angiography who are deemed suitable for PCI are assessed for eligibility. Patients fulfilling all inclusion and no exclusion criteria can be consented for trial participation. After successful lesion preparation, defined as residual stenosis less than 30%, TIMI flow 3 and no major (type C) dissection of target lesion, consented patients will be randomized in a 1:1 ratio to a drug eluting balloon(DEB)-based or standard drug eluting stent(DES)-based strategy and further randomized in a 1:1 fashion, stratified based on DEB vs DES, to undergo invasive follow-up at 6 (±30 days) or 12 (±30 days) months.
Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to DEB-based strategy will receive treatment with DEB (Magic Touch, Concept Medical®) throughout the entire lesion length, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
Device: Magic Touch drug eluting balloon based strategy
Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
Device: Drug-eluting stent-based strategy
Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
Absolute change of FFR values (ΔFFR)
Absolute change of fractional flow reserve (FFR) values (ΔFFR) measured at the final assessment immediately after the index PCI and invasive follow-up at 6(±30days) or 12(±30 days) months
Time frame: At 6(±30days) or 12(±30 days) months after the index PCI
QCA parameter (minimal lumen diameter, MLD, mm) before and after the intervention and at follow-up angiography
Minimal lumen diameter (MLD,mm) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
QCA parameter (maximal diameter stenosis, MaxS, percent) before and after the intervention and at follow-up angiography
Maximal diameter stenosis (MaxS, percent) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
QCA parameter (reference vessel diameter, RVD, mm) before and after the intervention and at follow-up angiography
Reference vessel diameter (RVD, mm) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
QCA parameter (lesion length, LL, mm) before and after the intervention and at follow-up angiography.
Lesion length (LL, mm) before the intervention, immediately after the intervention and at follow-up angiography.
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
QFR parameters before and after intervention and at follow-up angiography
Quantitative Flow Ratio (QFR) parameters before the intervention, immediately after the intervention and at follow-up angiography
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
FFR parameters before and after intervention and at follow-up angiography
Fractional Flow Reserve (FFR) parameters before the intervention, immediately after the intervention and at follow-up angiography
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Minimal lumen diameter (MLD, mm)
Minimal lumen diameter (MLD, mm) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Minimal luminal area (MLA, mm^2)
Minimal luminal area (MLA, mm\^2) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Maximal diameter stenosis (MaxS, percent)
Maximal diameter stenosis (MaxS, percent) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Lumen volume (LV, mm^3)
Lumen volume (LV, mm\^3) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Vessel volume (VV, mm^3)
Vessel volume (VV, mm\^3) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Plaque burden (VV-LV)
Plaque burden (VV-LV) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Late lumen loss (LLL)
Late lumen loss (LLL) evaluated with intravascular ultrasound (IVUS)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Acute gain
Variation between pre treatment (T0) and immediately after the treatment (Tf)
Time frame: pre procedure and immediately after the procedure
Disease progression after index PCI
Variation between final result of index PCI (Tf) and procedure at 6(±30days) or 12(±30 days) months after the index PCI (Tc)
Time frame: pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI
Target lesion revascularization (TLR) defined as urgent and non-urgent
Rate of target lesion revascularization (TLR) defined as urgent and non-urgent
Time frame: 5 years after the index PCI
Target vessel revascularization (TVR), defined as urgent and non-urgent
Rate of target vessel revascularization (TVR), defined as urgent and non-urgent
Time frame: 5 years after the index PCI
Target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization
Rate of target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization
Time frame: 5 years after the index PCI
The individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)
Rate of the individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)
Time frame: 5 years after the index PCI
Any myocardial infarction
Rate of any myocardial infarction
Time frame: 5 years after the index PCI
Stroke
Rate of stroke
Time frame: 5 years after the index PCI
Definite or probable stent thrombosis
Rate of definite or probable stent thrombosis
Time frame: 5 years after the index PCI
Started Feb 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiocentro Ticino